Accessibility Menu
RemeGen logo

RemeGen(OTC) REGMF

Current Price$11.49
Market Cap$6.42BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-26%
5 Year-26%
1 Year+127%
1 Month+21%
RemeGen last closing stock price
MetricPriceDate
Last closeUSD 11.492026-07-16
RemeGen stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+20.95%USD 9.502026-06-03
1 month+20.95%USD 9.502026-06-03
3 month+4.94%USD 10.952026-03-26
Year to date+17.13%USD 9.812025-12-26
1 year+127.08%USD 5.062025-04-25
3 year+187.25%USD 4.002023-07-05
5 year-26.49%USD 15.632021-01-21
Since inception-26.49%USD 15.632021-01-21

RemeGen Financials at a Glance

Market Cap

$6.42BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥3.35B

Net Income (TTM)

CN¥1.27B

EPS (TTM)

$0.33

P/E Ratio

35.03

Dividend

$0.00

Beta (Volatility)

0.06 (Low)

Price

$11.49

Volume

500

Open

$11.49

Previous Close

$11.49

Daily Range

$11.49 - $11.49

52-Week Range

$5.06 - $15.91

Estimated Earnings Date

Aug 25, 2026

REGMF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About RemeGen

RemeGen Co., Ltd. is a biopharmaceutical company based in Yantai, China, established in 2008. The firm specializes in the discovery, development, and commercialization of biologics aimed at addressing unmet medical needs in autoimmune, oncology, and ophthalmic diseases.

Products and Services
  • Telitacicept (RC18) for systemic lupus erythematosus
  • Disitamab Vedotin (RC48) for various cancers
  • Robust pipeline including candidates for multiple diseases
Growth Outlook
  • Phase III trials for Telitacicept in neuromyelitis optica spectrum disorder
  • Expansion into U.S. market enhances growth potential
  • Multiple candidates in clinical trials targeting significant diseases
Financial Highlights
  • Recent quarterly revenue of 649.94 million CNY, showing strong market demand
  • Net income of 324.87 million CNY in the latest quarter
  • TTM gross profit margin of 85.40%, indicating operational efficiency
RemeGen Co., Ltd. is positioned in the biotechnology sector, focusing on innovative treatments for serious health conditions. The company has made significant strides in clinical development, with several products in various stages of trials. The recent financial performance reflects a strong revenue stream and profitability, which may attract investor interest. The ongoing expansion into the U.S. market and a robust pipeline of candidates further enhance the company's growth potential. With a focus on addressing critical health issues, RemeGen is well-placed to capitalize on emerging opportunities in the biopharmaceutical landscape.
AI Generated • Jul 3, 2026

Industry

Biotechnology

Sector

Health Care

Employees

3,048

CEO

Jian Min Fang, PhD

Website

www.remegen.com

Headquarters

Yantai, SD, CN

REGMF Financials

Key Financial Metrics (TTM)

Gross Margin

85.40%

Operating Margin

9.06%

Net Income Margin

38.17%

Return on Equity

42.27%

Return on Capital

2.18%

Return on Assets

17.52%

Earnings Yield

2.85%

Dividend Yield

0.00%

Payout Ratio

1.38%

Stock Overview

Market Cap

$6.42BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

558.40M

Volume

500

Avg. Volume

80.645

Financials (TTM)

Gross Profit

CN¥2.86B

Operating Income

CN¥300.66M

EBITDA

CN¥472.49M

Operating Cash Flow

CN¥257.56M

Capital Expenditure

-CN¥210.64M

Free Cash Flow

CN¥46.80M

Cash & ST Invst.

CN¥2.73B

Total Debt

CN¥2.09B

RemeGen Performance Analysis

RemeGen annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 114,608,356-48.2%
20232023-12-31CNY 152,716,49433.3%
20242024-12-31CNY 237,626,14355.6%
20252025-12-31CNY 452,057,09790.2%
RemeGen sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-308.7%
Q32025-09-307.9%
Q42025-12-31144.5%
Q12026-03-31-56.9%
RemeGen annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY -0.28N/A
20232023-12-31CNY -0.4042.0%
20242024-12-31CNY -0.38-4.3%
20252025-12-31CNY 0.18N/A
RemeGen sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3019.6%
Q32025-09-3051.4%
Q42025-12-311361.1%
Q12026-03-31-74.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

CN¥649.94M

+23.6%

Gross Profit

CN¥534.10M

+22.0%

Gross Margin

82.18%

N/A

Market Cap

$6.42BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.10M

N/A

Employees

3,048

N/A

Net Income

CN¥324.87M

+227.8%

EBITDA

-CN¥25.64M

+84.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

CN¥2.73B

+278.9%

Total Debt

CN¥2.09B

-23.6%

Accounts Receivable

CN¥525.62M

-3.8%

Inventory

CN¥699.93M

+9.7%

Long Term Debt

CN¥744.91M

-32.1%

Short Term Debt

CN¥1.34B

-17.8%

Return on Assets

17.52%

N/A

Return on Invested Capital

6.43%

N/A

Free Cash Flow

-CN¥30.78M

+86.3%

Operating Cash Flow

CN¥13.85M

+107.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SHTDYSinopharm Group Co. Ltd.
$10.73+0.07%
TRSBF3SBio Inc.
$2.15+0.00%
KYKOFKyowa Kirin Co., Ltd.
$14.43+0.00%
ZLDPFZealand Pharma A/S
$45.02+0.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
TAT&T
$24.13+0.05%
FFord Motor Company
$14.37+0.02%

Questions About REGMF

What is the current price of RemeGen?

RemeGen is trading at $11.49 per share.

What is the 52-week range for RemeGen?

Over the past 52 weeks, RemeGen has traded between $5.06 and $15.91.

How much debt does RemeGen have?

As of the most recent reporting period, RemeGen reported total debt of CN¥303.17M.

How much cash does RemeGen have on hand?

RemeGen reported CN¥162.34M in cash and cash equivalents in its most recent financial results.

What is RemeGen’s dividend yield?

RemeGen does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services